| 259 |
Sensitization induction of the intestinal tract by food proteins |
Erwin Roggen |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 269 |
Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development |
Christopher Goodchild |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 270 |
Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity |
Christopher Goodchild |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 321 |
Reduced environmental pH leading to thinner shells in Mytilus edulis |
James Ducker |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 332 |
Formation of DNA photoproducts leading to growth inhibition (2) |
You Song |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 333 |
Formation of DNA photoproducts leading to growth inhibition (3) |
You Song |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 369 |
Photosystem II antagonism leading to growth inhibition via oxidative damage |
You Song |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 370 |
Photosystem II antagonism leading to growth inhibition via suppression of photosynthesis |
You Song |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 371 |
Photosystem II antagonism leading to growth inhibition via dysregulation of growth hormone |
You Song |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 373 |
Mitochondrial dysfunction to metabolic diseases |
Chander K. Negi |
Under Development: Contributions and Comments Welcome |
|
|
|
|
|
| 375 |
test AOP |
Kevin Crofton |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 378 |
Dysregulated underperforming Toll Like Receptors (TLRs) leading to high pathogen load |
Gillina Bezemer |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 393 |
AOP for thyroid disorder caused by triphenyl phosphate |
Fei Li |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 401 |
G protein-coupled estrogen receptor 1 (GPER) signal pathway in the endocrine disrupting effect |
Fei Li |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 402 |
Thyroid peroxidase (TPO) inhibition leads to periventricular heterotopia formation in the developing rat brain |
Katherine (Katie) O'Shaughnessy |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 403 |
combined unhealthy lifestyle factors leading to metabolic syndrome |
Gillina Bezemer |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 404 |
Metabolic Syndrome leading to Toll Like Receptor dysregulation |
Gillina Bezemer |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 406 |
SARS-CoV-2 infection leading to hyperinflammation |
Hasmik Yepiskoposyan |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 407 |
SARS-CoV-2 infection leading to pyroptosis |
Hasmik Yepiskoposyan |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 408 |
Imbalance in redox homeostasis leading to structural damage to tissues |
Fei Li |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 409 |
Frustrated phagocytosis leads to malignant mesothelioma |
Nureddin Mansour |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 410 |
Repression of Gbx2 expression leads to defects in developing inner ear and consequently to increased mortality |
Vid Modic |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 411 |
Oxidative stress [MIE] Leading to Decreased Lung Function [AO] |
Karsta Luettich |
Open for comment. Do not cite |
|
|
|
|
|
| 412 |
SARS-CoV-2 infection leading to thromboinflammation |
Luigi Margiotta-Casaluci |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 413 |
Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure |
Zarin Hossain |
Open for citation & comment |
|
|
|
|
|
| 414 |
Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway |
Dianke Yu |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 415 |
Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway |
Dianke Yu |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 416 |
Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway |
Dianke Yu |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 417 |
Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway |
Dianke Yu |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 418 |
Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway |
Dianke Yu |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 419 |
Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway |
Dianke Yu |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 420 |
Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway |
Dianke Yu |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 421 |
PPARG activation leading to intrahepatic cholestasis |
Yuan Jin |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 422 |
Binding of SARS-CoV-2 to ACE2 in enterocytes leads to increased intestinal permeability resulting in GI disorders |
Laure-Alix Clerbaux |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 423 |
Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway |
Fei Li |
Under development: Not open for comment. Do not cite |
|
|
|
|
|
| 211 |
Handbook development AOP |
Dan Villeneuve |
Under Development: Contributions and Comments Welcome |
Under Development |
|
|
|
1.29 |
| 4 |
Ecdysone receptor agonism leading to incomplete ecdysis associated mortality |
Knut Erik Tollefsen |
Open for citation & comment |
Under Development |
103: Increase, Ecdysone receptor agonism |
|
|
|
| 262 |
L-type calcium channel blockade leading to the disruption of cardiac electrophysiology |
Luigi Margiotta-Casaluci |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
|
|
Under Development |
1.45 |
| 11 |
Percellome Toxicogenomics Approach for AOP Building: Case study on Pentachlorophenol |
Jun Kanno |
Not under active development |
Included in OECD Work Plan |
245: Activation, PXR/SXR |
|
Under Development |
2.5 |
| 21 |
Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 |
Markus Hecker |
Open for citation & comment |
Included in OECD Work Plan |
18: Activation, AhR |
|
WPHA/WNT Endorsed |
1.27 |
| 283 |
L-type calcium channel blockade leading to hypotension |
Luigi Margiotta-Casaluci |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
|
|
Under Development |
1.45 |
| 32 |
Inhibition of iNOS, hepatotoxicity, and regenerative proliferation leading to liver tumors |
Michelle Embry |
Not under active development |
Under Development |
|
|
|
|
| 35 |
Narcosis leading to respiratory failure |
Dries Knapen |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
46: Accumulation, Biological membranes |
|
Under Development |
1.2 |
| 295 |
Early-life stromal estrogen receptor activation by endocrine disrupting chemicals in the mammary gland leading to enhanced cancer risk |
Andrea Hindman |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
|
|
Under Development |
1.79 |
| 53 |
ER agonism leading to reduced survival due to renal failure |
Tom Hutchinson |
Under Development: Contributions and Comments Welcome |
Under Development |
111: Agonism, Estrogen receptor |
|
|
1.29 |
| 59 |
HNF4alpha suppression leading to hepatic steatosis |
Michelle Angrish |
Under Development: Contributions and Comments Welcome |
Under Development |
461: Suppression, HNF4alpha |
|
|
1.29 |
| 323 |
PPARalpha Agonism Impairs Fish Reproduction |
Ashley Kittelson |
Open for citation & comment |
|
227: Activation, PPARα |
|
|
|
| 385 |
ACE2 dysregulation leading to microvascular disfunction |
Julija Filipovska |
Under development: Not open for comment. Do not cite |
|
1739: ACE2 binding to viral S-protein |
|
|
|
| 146 |
Estrogen Receptor Activation and Female Precocious Puberty |
Jeff Welch |
Under Development: Contributions and Comments Welcome |
Under Development |
|
|
|
1.29 |
| 163 |
PPARgamma activation leading to sarcomas in rats, mice, and hamsters |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
1028: Activation of specific nuclear receptors, PPAR-gamma activation |
|
|
1.29 |
| 197 |
Sodium channel (Nav1.1) inhibition leading to population decline |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
584: Inhibition, sodium channel |
|
|
1.29 |
| 199 |
ER mediated breast cancer AOP |
Molly M Morgan |
Under development: Not open for comment. Do not cite |
Under Development |
|
|
|
|
| 239 |
Oxidative Stress Leading to ILC2-mediated Respiratory Epithelial Remodeling |
Annie Jarabek |
Under development: Not open for comment. Do not cite |
Under Development |
|
|
|
|
| 240 |
DNA Adducts Leading to Liver Hemangiosarcoma |
Annie Jarabek |
Under development: Not open for comment. Do not cite |
Under Development |
|
|
|
|
| 43 |
Disruption of VEGFR Signaling Leading to Developmental Defects |
Tom Knudsen |
Open for citation & comment |
Included in OECD Work Plan |
305: Inhibition, VegfR2 |
1001: Increased, Developmental Defects |
EAGMST Under Review |
1.6 |
| 162 |
Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
|
1026: Increased Apoptosis, Adenomas/carcinomas (follicular cell) |
|
1.29 |
| 164 |
Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
1038: Activation, beta-2 adrenergic receptor |
1044: Promotion, mesovarian leiomyomas |
|
1.29 |
| 165 |
Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
|
1053: Promotion, ovarian adenomas and 1054: Promotion, ovarian granular cell tumors |
|
1.29 |
| 166 |
PPARalpha activation leading to pancreatic acinar tumors in the rat and mouse |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
|
1063: Increased, Pancreatic acinar tumors |
|
1.29 |
| 167 |
Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
1064: prepubertal increase, Estrogen receptor (ER) activity |
1070: Increased, adenosquamous carcinomas of endometrium |
|
1.29 |
| 168 |
GnRH pulse disruption leading to mammary adenomas and carcinomas in the SD rat. |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
|
1079: Increased, Adenomas/carcinomas (mammary) |
|
1.29 |
| 170 |
Anti-dopaminergic activity leading to mammary adenomas and carcinomas in the SD rat |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
|
1079: Increased, Adenomas/carcinomas (mammary) |
|
1.29 |
| 169 |
GnRH pulse disruption leading to pituitary adenomas and carcinomas in the SD rat. |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
|
1082: Increased, adenomas (pituitary) |
|
1.29 |
| 171 |
Chronic cytotoxicity of the serous membrane leading to pleural/peritoneal mesotheliomas in the rat. |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
|
1090: Increased, mesotheliomas |
|
1.29 |
| 366 |
Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under development: Not open for comment. Do not cite |
|
957: Binding, Transthyretin in serum |
1101: Altered, Amphibian metamorphosis |
|
|
| 367 |
Competitive binding to thyroid hormone carrier protein thyroid binding globulin (TBG) leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under development: Not open for comment. Do not cite |
|
1831: Binding, Thyroid binding globulin in serum |
1101: Altered, Amphibian metamorphosis |
|
|
| 175 |
Thyroperoxidase inhibition leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under Development: Contributions and Comments Welcome |
Under Development |
279: Thyroperoxidase, Inhibition |
1101: Altered, Amphibian metamorphosis |
|
1.29 |
| 176 |
Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under Development: Contributions and Comments Welcome |
Under Development |
424: Inhibition, Na+/I- symporter (NIS) |
1101: Altered, Amphibian metamorphosis |
|
1.29 |
| 188 |
Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under Development: Contributions and Comments Welcome |
Under Development |
1152: Inhibition, Iodotyrosine deiodinase (IYD) |
1101: Altered, Amphibian metamorphosis |
|
1.29 |
| 189 |
Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under Development: Contributions and Comments Welcome |
Under Development |
1009: Inhibition, Deiodinase 1 |
1101: Altered, Amphibian metamorphosis |
|
1.29 |
| 190 |
Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under Development: Contributions and Comments Welcome |
Under Development |
1002: Inhibition, Deiodinase 2 |
1101: Altered, Amphibian metamorphosis |
|
1.29 |
| 191 |
Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under Development: Contributions and Comments Welcome |
Under Development |
1153: Inhibition, Deiodinase 3 |
1101: Altered, Amphibian metamorphosis |
|
1.29 |
| 192 |
Pendrin inhibition leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under Development: Contributions and Comments Welcome |
Under Development |
1155: Inhibition, Pendrin |
1101: Altered, Amphibian metamorphosis |
|
1.29 |
| 193 |
Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under Development: Contributions and Comments Welcome |
Under Development |
1156: Inhibition, Dual oxidase |
1101: Altered, Amphibian metamorphosis |
|
1.29 |
| 194 |
Hepatic nuclear receptor activation leading to altered amphibian metamorphosis |
Jonathan Haselman |
Under Development: Contributions and Comments Welcome |
Under Development |
1157: Activation, Hepatic nuclear receptor(s) |
1101: Altered, Amphibian metamorphosis |
|
1.29 |
| 187 |
Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage |
Barnett Rattner |
Not under active development |
Included in OECD Work Plan |
1134: Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone and 1138: Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP and 1169: |
1136: Impaired recruitment , Population trajectory |
Under Development |
1.31 |
| 203 |
5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
619: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
1141: Decreased, Reproductive Success and 361: Decline, Population |
|
1.29 |
| 204 |
5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
619: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
1163: Increased, Reproductive Success and 1164: Increased, Population |
|
1.29 |
| 195 |
5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
619: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
1164: Increased, Population |
|
1.29 |
| 200 |
Estrogen receptor activation leading to breast cancer |
Molly M Morgan |
Open for adoption |
Under Development |
1181: Activation, Estrogen receptor |
1193: N/A, Breast Cancer |
|
|
| 294 |
Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer |
Jessica Helm |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1632: Increase in reactive oxygen and nitrogen species (RONS) |
1194: Increase, DNA damage and 185: Increase, Mutations and 1192: Increased, Ductal Hyperplasia and 1193: N/A, Breast Cancer |
Under Development |
1.80 |
| 201 |
Juvenile hormone receptor agonism leading to male offspring induction associated population decline |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
Under Development |
1205: Activation, Juvenile hormone receptor |
1208: Increased, Male offspring and 361: Decline, Population and 1210: Alteration, Food-web structures |
|
|
| 196 |
Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation |
Jeanelle Martinez |
Under development: Not open for comment. Do not cite |
Under Development |
1215: TRPA1 activation, TRPA1 Receptor |
1223: Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea and 1434: Irritation of nasal mucosa inducing sneeze reflex and 1226: Increased Respiratory irritability and Chronic Cough, |
|
|
| 302 |
Lung surfactant function inhibition leading to decreased lung function |
Jorid Birkelund Sørli |
Open for comment. Do not cite |
Included in OECD Work Plan |
1672: Inhibition of lung surfactant function |
1250: Decrease, Lung function |
Under Development |
1.87 |
| 148 |
EGFR Activation Leading to Decreased Lung Function |
Karsta Luettich |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
941: Activation, EGFR |
1250: Decrease, Lung function |
Under Development |
1.51 |
| 202 |
Inhibitor binding to topoisomerase II leading to infant leukaemia |
Andrea Terron |
Open for comment. Do not cite |
Included in OECD Work Plan |
1252: Binding to (interferes with) topoisomerase II enzyme |
1254: Infant leukaemia |
EAGMST Under Review |
1.53 |
| 205 |
AOP from chemical insult to cell death |
Mathieu Vinken |
Open for comment. Do not cite |
Under Development |
1258: Decompartmentalization and 1260: Direct mitochondrial inhibition and 1259: narcosis |
1262: Apoptosis and 1263: Necrosis |
|
|
| 319 |
Inhibition of Angiotensin-converting enzyme 2 leading to lung fibrosis |
Young Jun Kim |
Open for comment. Do not cite |
|
1740: ACE2 inhibition |
1276: Lung fibrosis |
|
|
| 382 |
Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis |
Young Jun Kim |
Under development: Not open for comment. Do not cite |
|
1851: Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) |
1276: Lung fibrosis |
|
|
| 206 |
Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis |
Jinhee Choi |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1270: Inactivation of PPARγ |
1276: Lung fibrosis |
Under Development |
1.54 |
| 207 |
NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans |
Jinhee Choi |
Under development: Not open for comment. Do not cite |
Under Development |
1174: Activation, NADPH Oxidase |
1277: Reproductive failure |
|
|
| 208 |
Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) and Transforming growth factor (TGF)-beta pathways activation leading to reproductive failure |
Jinhee Choi |
Under development: Not open for comment. Do not cite |
Under Development |
|
1277: Reproductive failure |
|
|
| 210 |
Activation of c-Jun N-terminal kinase (JNK) and Forkhead box O (FOXO) and reduction of WNT pathways leading to reproductive failure: Integrated multi-OMICS approach for AOP building |
Jinhee Choi |
Under development: Not open for comment. Do not cite |
Under Development |
|
1277: Reproductive failure |
|
|
| 209 |
Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP |
Jinhee Choi |
Under development: Not open for comment. Do not cite |
Under Development |
|
1291: Hepatotoxicity |
|
|
| 226 |
SSRI (Selective serotonin reuptake inhibitor) to hypertension |
Lyle Burgoon |
Open for adoption |
Under Development |
1317: Decreased, serotonin transporter activity |
1343: Increase, hypertension |
|
|
| 223 |
Serotonin transporter activation to seizure |
Lyle Burgoon |
Open for adoption |
Under Development |
1397: Increased, serotonin transporter activity |
1344: Increased, seizure |
|
|
| 214 |
Network of SSRIs (selective serotonin reuptake inhibitors) |
Lyle Burgoon |
Open for adoption |
Under Development |
|
1344: Increased, seizure and 1345: Increased, agitation and 1346: Increased, depression and 1343: Increase, hypertension |
|
|
| 222 |
Mental stress to agitation |
Lyle Burgoon |
Open for adoption |
Under Development |
1396: Increased, glucocorticoid receptor activity |
1345: Increased, agitation |
|
|
| 225 |
Serotonin transporter activation to agitation |
Lyle Burgoon |
Open for adoption |
Under Development |
|
1345: Increased, agitation |
|
|
| 221 |
Mental stress to depression |
Lyle Burgoon |
Open for adoption |
Under Development |
1396: Increased, glucocorticoid receptor activity |
1346: Increased, depression |
|
|
| 224 |
Serotonin transporter activation to depression |
Lyle Burgoon |
Open for adoption |
Under Development |
1397: Increased, serotonin transporter activity |
1346: Increased, depression |
|
|
| 215 |
Molecular events lead to epilepsy |
Lyle Burgoon |
Open for adoption |
Under Development |
|
1348: Increase, seizure and 1362: Increased, hippocampal hyperdepolarization and 1363: Increased, epilepsy |
|
|
| 230 |
presynaptic neuron 1 activation to epilepsy |
Lyle Burgoon |
Open for adoption |
Under Development |
1349: Activated, presynaptic neuron 1 |
1363: Increased, epilepsy |
|
|
| 231 |
presynaptic neuron 2 repression to epilepsy |
Lyle Burgoon |
Open for adoption |
Under Development |
1413: Reduced, presynaptic neuron 2 activity |
1363: Increased, epilepsy |
|
|
| 217 |
Gastric ulcer formation |
Lyle Burgoon |
Open for adoption |
Under Development |
|
1367: Inhibit, gastric ulcer formation and 1385: Activated, gastric ulcer formation |
|
|
| 227 |
NSAID induced PTGS1 inactivation to gastric ulcer |
Lyle Burgoon |
Open for adoption |
Under Development |
1402: Reduced, PTGS1 function |
1385: Activated, gastric ulcer formation |
|
|
| 228 |
NSAID induced PTGS2 inactivation to gastric ulcer |
Lyle Burgoon |
Open for adoption |
Under Development |
1408: Reduced, PTGS2 function |
1385: Activated, gastric ulcer formation |
|
|
| 229 |
Helicobacter pylori to gastric ulcer |
Lyle Burgoon |
Open for adoption |
Under Development |
1412: Helicobacter pylori infection |
1385: Activated, gastric ulcer formation |
|
|
| 220 |
Cyp2E1 Activation Leading to Liver Cancer |
Francina Webster |
Open for citation & comment |
Included in OECD Work Plan |
1391: Activation of Cyp2E1 |
1395: Liver Cancer |
EAGMST Under Review |
1.24 |
| 232 |
NFE2/Nrf2 repression to steatosis |
Lyle Burgoon |
Open for adoption |
Under Development |
1417: NFE2/Nrf2 repression |
1418: Increased, steatosis |
|
|
| 233 |
Mu Opioid Receptor Agonism leading to Analgesia via K Channel Opening |
Timothy Allen |
Not under active development |
Under Development |
1425: Mu Opioid Receptor Agonism |
1428: Analgesia |
|
|
| 234 |
Mu Opioid Receptor Agonism leading to Analgesia via Ca Channel Inhibition |
Timothy Allen |
Not under active development |
Under Development |
1425: Mu Opioid Receptor Agonism |
1428: Analgesia |
|
|
| 235 |
Serotonin 1A Receptor Agonism leading to Anti-depressant Activity via K Channel Opening |
Timothy Allen |
Not under active development |
Under Development |
1431: Serotonin 1A Receptor Agonism |
1432: Anti-depressant Activity |
|
|
| 236 |
Serotonin 1A Receptor Agonism leading to Anti-depressant Activity via Ca Channel Inhibition |
Timothy Allen |
Not under active development |
Under Development |
1431: Serotonin 1A Receptor Agonism |
1432: Anti-depressant Activity |
|
|
| 237 |
Secretion of inflammatory cytokines after cellular sensing of the stressor leading to plaque progression |
Sarah Søs Poulsen |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1437: Sensing of the stressor by pulmonary cells |
1443: Plaque progression in arteries |
Under Development |
1.55 |
| 72 |
Epigenetic modification of PPARG leading to adipogenesis |
Michelle Angrish |
Under Development: Contributions and Comments Welcome |
Under Development |
228: peroxisome proliferator activated receptor promoter demethylation and 1454: chronic high fat diet |
1447: obesity |
|
1.29 |
| 347 |
Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis |
Seokjoo Yoon |
Under development: Not open for comment. Do not cite |
|
1792: Toll-like receptor 4 activation and 1270: Inactivation of PPARγ |
1458: Pulmonary fibrosis |
|
|
| 173 |
Substance interaction with the lung resident cell membrane components leading to lung fibrosis |
Sabina Halappanavar |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1495: Interaction with the lung resident cell membrane components |
1458: Pulmonary fibrosis |
EAGMST Under Review |
1.32 |
| 241 |
Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis |
Marvin Martens |
Under development: Not open for comment. Do not cite |
|
1468: Activation, Latent Transforming Growth Factor Beta 1 |
1458: Pulmonary fibrosis |
|
|
| 242 |
Inhibition of lysyl oxidase leading to enhanced chronic fish toxicity |
Stefan Scholz |
Open for adoption |
|
1462: Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts |
1467: Growth, reduction and 636: Decreased, survival |
|
|
| 213 |
Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) |
Lyle Burgoon |
Open for adoption |
Under Development |
1490: Inhibition, Fatty Acid Beta Oxidation |
1489: N/A, Steatohepatisis |
|
|
| 212 |
Histone deacetylase inhibition leading to testicular atrophy |
Shihori Tanabe |
Open for citation & comment |
Included in OECD Work Plan |
1502: Histone deacetylase inhibition |
1506: Testicular atrophy |
EAGMST Under Review |
1.52 |
| 260 |
CYP2E1 activation and formation of protein adducts leading to neurodegeneration |
Jelle Broeders |
Under development: Not open for comment. Do not cite |
|
1508: CYP2E1 Activation and 1509: Protein Adduct Formation |
1514: Neurodegeneration |
|
|
| 263 |
Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation |
You Song |
Open for comment. Do not cite |
Included in OECD Work Plan |
1446: Decrease, Coupling of oxidative phosphorylation |
1521: Decrease, Growth |
EAGMST Under Review |
1.92 |
| 264 |
Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cell death |
You Song |
Open for citation & comment |
Included in OECD Work Plan |
1446: Decrease, Coupling of oxidative phosphorylation |
1521: Decrease, Growth |
Under Development |
1.92 |
| 265 |
Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased lipid storage |
You Song |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1446: Decrease, Coupling of oxidative phosphorylation |
1521: Decrease, Growth |
Under Development |
1.92 |
| 266 |
Uncoupling of oxidative phosphorylation leading to growth inhibition via oxidative DNA damage |
You Song |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1446: Decrease, Coupling of oxidative phosphorylation |
1521: Decrease, Growth |
Under Development |
1.92 |
| 267 |
Uncoupling of oxidative phosphorylation leading to growth inhibition via increased lipid peroxidation |
You Song |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1446: Decrease, Coupling of oxidative phosphorylation |
1521: Decrease, Growth |
Under Development |
1.92 |
| 268 |
Uncoupling of oxidative phosphorylation leading to growth inhibition via increased protein oxidation |
You Song |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1446: Decrease, Coupling of oxidative phosphorylation |
1521: Decrease, Growth |
Under Development |
1.92 |
| 286 |
Mitochondrial complex III antagonism leading to growth inhibition (1) |
You Song |
Under development: Not open for comment. Do not cite |
Under Development |
1542: Increase, Mitochondrial complex III antagonism |
1521: Decrease, Growth |
|
|
| 287 |
Mitochondrial complex III antagonism leading to growth inhibition (2) |
You Song |
Under development: Not open for comment. Do not cite |
Under Development |
1542: Increase, Mitochondrial complex III antagonism |
1521: Decrease, Growth |
|
|
| 290 |
Mitochondrial ATP synthase antagonism leading to growth inhibition (1) |
You Song |
Under development: Not open for comment. Do not cite |
Under Development |
1785: Increase, Mitochondrial ATP synthase antagonism |
1521: Decrease, Growth |
|
|
| 291 |
Mitochondrial ATP synthase antagonism leading to growth inhibition (2) |
You Song |
Under development: Not open for comment. Do not cite |
Under Development |
1785: Increase, Mitochondrial ATP synthase antagonism |
1521: Decrease, Growth |
|
|
| 245 |
Reduction in photophosphorylation leading to growth inhibition in aquatic plants |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
|
1471: Increase, Uncoupling of photophosphorylation |
1521: Decrease, Growth |
|
|
| 261 |
L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility |
Luigi Margiotta-Casaluci |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1529: Blockade, L-Type Calcium Channels |
1535: Heart failure |
Under Development |
1.45 |
| 273 |
Mitochondrial complex inhibition leading to liver injury |
Wanda van der Stel |
Under development: Not open for comment. Do not cite |
|
1542, 1543, 1544, 888, 887, 1653, 1654, 1655 |
1548: Necrotic Tissue and 1549: Liver Injury |
|
|
| 278 |
IKK complex inhibition leading to liver injury |
Nanette Vrijenhoek |
Under development: Not open for comment. Do not cite |
|
1574: Inhibition, IKK complex |
1548: Necrotic Tissue and 1549: Liver Injury |
|
|
| 285 |
Inhibition of N-linked glycosylation leads to liver injury |
Marvin Martens |
Under development: Not open for comment. Do not cite |
|
1604: Inhibition of N-linked glycosylation |
1549: Liver Injury |
|
|
| 272 |
Deposition of energy leading to lung cancer |
Vinita Chauhan |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1686: Direct Deposition of Energy |
1556: Increase, lung cancer |
EAGMST Under Review |
1.56 |
| 274 |
Histone deacetylase inhibition leads to impeded craniofacial development |
Marvin Martens |
Under development: Not open for comment. Do not cite |
|
1502: Histone deacetylase inhibition |
1559: Facial cartilage structures are reduced in size and morphologically distorted |
|
|
| 275 |
Histone deacetylase inhibition leads to neural tube defects |
Marvin Martens |
Under development: Not open for comment. Do not cite |
|
1502: Histone deacetylase inhibition |
1561: Neural tube defects |
|
|
| 276 |
Inhibition of complex I of the electron transport chain leading to chemical induced Fanconi syndrome |
Marvin Martens |
Under development: Not open for comment. Do not cite |
|
888: Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) |
1564: Chemical induced Fanconi syndrome |
|
|
| 279 |
Microtubule interacting drugs lead to peripheral neuropathy |
Marvin Martens |
Under development: Not open for comment. Do not cite |
|
1580: Binding of microtubule stabilizing agents (MSA) to microtubules |
1583: Sensory axonal peripheral neuropathy |
|
|
| 280 |
α-diketone-induced bronchiolitis obliterans |
Marvin Martens |
Under development: Not open for comment. Do not cite |
|
1584: Interaction of α-diketones with arginine residues |
1588: Bronchiolitis obliterans |
|
|
| 282 |
Reactive oxygen species generated from photoreactive chemicals leading to phototoxic reactions |
Satomi Onoue |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1592: ROS generation from photoactivated chemicals |
1599: Inflamatory events in light-exposed tissues |
EAGMST Under Review |
1.49 |
| 284 |
Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress leads to chronic kidney disease |
Frederic Y. Bois |
Under development: Not open for comment. Do not cite |
|
1487: Binding, Thiol/seleno-proteins involved in protection against oxidative stress |
1603: Chronic kidney disease |
|
|
| 384 |
Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease |
Young Jun Kim |
Under development: Not open for comment. Do not cite |
|
1853: Hyperactivation of ACE/Ang-II/AT1R axis |
1603: Chronic kidney disease |
|
|
| 288 |
Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) |
Bérénice COLLET |
Open for citation & comment |
|
1609: Inhibition, Cytochrome P450 enzyme (CYP17A1) activity |
1616: Malformation, cryptorchidism - maldescended testis |
|
|
| 298 |
Chronic reactive oxygen species leading to human treatment-resistant gastric cancer |
Shihori Tanabe |
Open for comment. Do not cite |
Included in OECD Work Plan |
1753: Chronic reactive oxygen species |
1651: Treatment-resistant gastric cancer |
EAGMST Under Review |
1.58 |
| 301 |
Inhibition of Cystathionine Beta synthase leading to impaired the early development of anterior-posterior axis |
Young Jun Kim |
Under development: Not open for comment. Do not cite |
|
1657: Inhibition of cystathionine beta-synthase |
1667: Impaired,anterior-posterior axis development |
|
|
| 303 |
Frustrated phagocytosis-induced lung cancer |
Carole Seidel |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1668: Frustrated phagoytosis |
1670: Lung cancer |
Under Development |
1.86 |
| 304 |
TBX1 inhibition leading to congenital cardiac conotruncal anomalies |
Jinsoo Lee |
Under development: Not open for comment. Do not cite |
|
1680: Inhibition, TBX1 |
1685: Anomalies, Congenital cardiac conotruncal |
|
|
| 305 |
5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring |
Terje Svingen |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1617: 5α-reductase, inhibition |
1688: decrease, male anogenital distance |
Under Development |
1.90 |
| 306 |
Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring |
Terje Svingen |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
26: Antagonism, Androgen receptor |
1688: decrease, male anogenital distance |
Under Development |
1.90 |
| 307 |
Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring |
Terje Svingen |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
|
1688: decrease, male anogenital distance |
Under Development |
1.90 |
| 396 |
Deposition of ionizing energy leads to population decline via impaired meiosis |
Erica Maremonti |
Under development: Not open for comment. Do not cite |
|
1550: Direct Deposition of Ionizing Energy and 1115: Increased, Reactive oxygen species and 1194: Increase, DNA damage |
1696: Decrease of egg production and cummulative fecundity and 997: Decreased, Population size |
|
|
| 313 |
Stimulation of TLR7/8 in dendric cells leading to Psoriatic skin disease |
Hiroyuki Komatsu |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1706: Stimulation, TLR7/8 |
1709: Psoriatic skin disease |
Under Development |
1.75 |
| 314 |
Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) |
Yasuharu Otsubo |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1710: Binding to estrogen receptor (ER)-α in immune cells |
1714: Exacerbation of systemic lupus erythematosus (SLE) |
Under Development |
1.73 |
| 315 |
Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response |
Yasuhiro Yoshida |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1715: Inhibition of JAK3 |
1719: Impairment of T-cell dependent antibody response |
Under Development |
1.74 |
| 316 |
Trypsin inhibition leading to pancreatic acinar cell tumors |
Shigeru Hisada |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1720: Trypsin inhibition |
1725: Pancreatic acinar cell tumors |
Under Development |
1.60 |
| 322 |
Alkylation of DNA leading to reduced sperm count |
Carole Yauk |
Under development: Not open for comment. Do not cite |
|
97: Alkylation, DNA |
1757: Reduce, Sperm count |
|
|
| 400 |
Increased (ectopic) concentration of all-trans retinoic acid (ATRA) if fetal testis leading to reduced sperm count, males |
Terje Svingen |
Under development: Not open for comment. Do not cite |
|
1888: Increased (ectopic) all-trans retinoic acid concentration |
1757: Reduce, Sperm count |
|
|
| 335 |
AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment |
Nathalia Pereira Souza |
Under development: Not open for comment. Do not cite |
|
1261: Mitochondrial impairment |
1763: Urothelial Tumor |
|
|
| 340 |
DNA methyltransferase inhibition leading to transgenerational effects (1) |
You Song |
Under Development: Contributions and Comments Welcome |
Under Development |
1619: Increase, DNA methyltransferase inhibition |
1781: Decrease, Fecundity (F3) and 360: Decrease, Population trajectory |
|
|
| 341 |
DNA methyltransferase inhibition leading to transgenerational effects (2) |
You Song |
Under Development: Contributions and Comments Welcome |
Under Development |
1619: Increase, DNA methyltransferase inhibition |
1781: Decrease, Fecundity (F3) and 360: Decrease, Population trajectory |
|
|
| 344 |
Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring |
Terje Svingen |
Under development: Not open for comment. Do not cite |
|
26: Antagonism, Androgen receptor |
1786: increase, retained nipples in males |
|
|
| 362 |
Immune mediated hepatitis |
Jung-Hwa Oh |
Under development: Not open for comment. Do not cite |
|
1814: benzoquinone imine and acylglucuronide metabolites |
1820: Immune mediated hepatitis |
|
|
| 372 |
Androgen receptor antagonism leading to testicular cancer |
Chander K. Negi |
Under development: Not open for comment. Do not cite |
|
26: Antagonism, Androgen receptor |
1839: Testicular Cancer |
|
|
| 374 |
Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis |
Anna Price |
Under development: Not open for comment. Do not cite |
|
1739: ACE2 binding to viral S-protein |
1841: Encephalitis |
|
|
| 377 |
Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Acute Respiratory Distress Syndrome (ARDS) and Multiple Organ Dysfunction (MOD) |
Gillina Bezemer |
Under development: Not open for comment. Do not cite |
|
1842: Prolonged TLR9 activation |
1843: Acute Respiratory Distress Syndrome and Multiple Organ Dysfunction and 351: Increased Mortality |
|
|
| 379 |
Increased susceptibility to viral entry and coronavirus production leading to thrombosis and disseminated intravascular coagulation |
Shihori Tanabe |
Under development: Not open for comment. Do not cite |
|
1738: Increased susceptibility to viral entry |
1847: Increased coronavirus production and 1846: Thrombosis and Disseminated Intravascular Coagulation |
|
|
| 397 |
Bulky DNA adducts leading to mutations |
Carole Yauk |
Under development: Not open for comment. Do not cite |
|
1879: Bulky DNA adducts, increase |
185: Increase, Mutations |
|
|
| 293 |
Increased DNA damage leading to increased risk of breast cancer |
Jessica Helm |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1194: Increase, DNA damage |
185: Increase, Mutations and 1192: Increased, Ductal Hyperplasia and 1193: N/A, Breast Cancer |
Under Development |
1.80 |
| 296 |
Oxidative DNA damage leading to chromosomal aberrations and mutations |
Carole Yauk |
Open for comment. Do not cite |
Included in OECD Work Plan |
1634: Increase, Oxidative damage to DNA |
185: Increase, Mutations and 1636: Increase, Chromosomal aberrations |
EAGMST Under Review |
1.76 |
| 381 |
Binding of viral S-glycoprotein to ACE2 receptor leading to dysgeusia |
Young Jun Kim |
Under development: Not open for comment. Do not cite |
|
1739: ACE2 binding to viral S-protein |
1850: dysgeusia |
|
|
| 386 |
Increased reactive oxygen species production leading to population decline via inhibition of photosynthesis |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
|
257: Increase, Reactive Oxygen Species production |
1863: Decrease, Reproduction and 360: Decrease, Population trajectory |
|
|
| 387 |
Increased reactive oxygen species production leading to population decline via mitochondrial dysfunction |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
|
257: Increase, Reactive Oxygen Species production |
1863: Decrease, Reproduction and 360: Decrease, Population trajectory |
|
|
| 388 |
DNA damage leading to population decline via programmed cell death |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
|
1194: Increase, DNA damage |
1863: Decrease, Reproduction and 360: Decrease, Population trajectory |
|
|
| 389 |
Oxygen-evolving complex damage leading to population decline via inhibition of photosynthesis |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
|
1865: Increase, Oxygen-evolving complex damage |
1863: Decrease, Reproduction and 360: Decrease, Population trajectory |
|
|
| 392 |
Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation |
Penny Nymark |
Under development: Not open for comment. Do not cite |
|
1866: Fibrinolysis, decreased and 1867: Bradykinin system, hyperactivated |
1868: Hyperinflammation |
|
|
| 394 |
Sars-cov-2 infection leading to impaired olfactory function (anosmia) |
Sandra Coecke |
Under development: Not open for comment. Do not cite |
|
1739: ACE2 binding to viral S-protein |
1873: impaired olfactory function (anosmia) |
|
|
| 395 |
Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on pericytes leads to disseminated intravascular coagulation resulting in cerebrovascular disease (stroke) |
Magda Sachana |
Under development: Not open for comment. Do not cite |
|
1739: ACE2 binding to viral S-protein |
1875: Cerebrovascular disease (stroke) |
|
|
| 151 |
AhR activation leading to preeclampsia |
Sabrina Tait |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
18: Activation, AhR |
1893: increase, Preeclampsia |
Under Development |
1.42 |
| 28 |
Cyclooxygenase inhibition leading reproductive failure |
Dan Villeneuve |
Under Development: Contributions and Comments Welcome |
Under Development |
79: Inhibition, Cyclooxygenase activity |
253: N/A, Reproductive failure |
|
1.29 |
| 39 |
Covalent Binding of Low Molecular Weight Organic Chemicals to Proteins leads to Sensitisation (Sensitization) of the Respiratory Tract |
Kristie Sullivan |
Under Development: Contributions and Comments Welcome |
Included in OECD Work Plan |
396: Covalent Binding, Protein |
313: Increase, Allergic Respiratory Hypersensitivity Response |
Under Development |
1.20 |
| 8 |
Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals |
Katie Paul Friedman |
Not under active development |
Included in OECD Work Plan |
239: Activation, Pregnane-X receptor, NR1l2 |
319: Loss, Cochlear function |
Under Development |
1.9 |
| 31 |
Oxidation of iron in hemoglobin leading to hematotoxicity |
Mitchell S. Wilbanks |
Open for adoption |
Included in OECD Work Plan |
213: N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III) |
321: N/A, Cyanosis occurs |
Under Development |
1.16 |
| 14 |
Glucocorticoid Receptor Activation Leading to Increased Disease Susceptibility |
Carlie LaLone |
Open for comment. Do not cite |
|
122: Activation, Glucocorticoid Receptor |
323: Increased, Disease susceptibility |
|
1.29 |
| 299 |
Excessive reactive oxygen species production leading to population decline via reduced fatty acid beta-oxidation |
You Song |
Under development: Not open for comment. Do not cite |
Under Development |
257: Increase, Reactive Oxygen Species production |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 311 |
Excessive reactive oxygen species production leading to population decline via mitochondrial dysfunction |
You Song |
Under development: Not open for comment. Do not cite |
|
257: Increase, Reactive Oxygen Species production |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 324 |
Thermal stress leading to population decline (1) |
You Song |
Under development: Not open for comment. Do not cite |
|
177: N/A, Mitochondrial dysfunction 1 |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 325 |
Thermal stress leading to population decline (2) |
You Song |
Under development: Not open for comment. Do not cite |
|
177: N/A, Mitochondrial dysfunction 1 |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 326 |
Thermal stress leading to population decline (3) |
You Song |
Under development: Not open for comment. Do not cite |
|
177: N/A, Mitochondrial dysfunction 1 |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 336 |
DNA methyltransferase inhibition leading to population decline (1) |
You Song |
Under Development: Contributions and Comments Welcome |
Under Development |
1619: Increase, DNA methyltransferase inhibition |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 337 |
DNA methyltransferase inhibition leading to population decline (2) |
You Song |
Under Development: Contributions and Comments Welcome |
Under Development |
1619: Increase, DNA methyltransferase inhibition |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 338 |
DNA methyltransferase inhibition leading to population decline (3) |
You Song |
Under Development: Contributions and Comments Welcome |
|
1619: Increase, DNA methyltransferase inhibition |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 339 |
DNA methyltransferase inhibition leading to population decline (4) |
You Song |
Under Development: Contributions and Comments Welcome |
Under Development |
1619: Increase, DNA methyltransferase inhibition |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 216 |
Excessive reactive oxygen species production leading to population decline via follicular atresia |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
Under Development |
257: Increase, Reactive Oxygen Species production |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 238 |
Excessive reactive oxygen species production leading to population decline via lipid peroxidation |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
|
257: Increase, Reactive Oxygen Species production |
328: Decrease, Fecundity and 360: Decrease, Population trajectory |
|
|
| 124 |
HMG-CoA reductase inhibition leading to decreased fertility |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
804: Inhibition, HMG-CoA reductase |
330: Decrease, Fertility |
|
1.29 |
| 15 |
Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations |
Carole Yauk |
Open for citation & comment |
Included in OECD Work Plan |
97: Alkylation, DNA |
336: Increase, Heritable mutations in offspring |
WPHA/WNT Endorsed |
1.11 |
| 19 |
Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) |
Mukesh Patel |
Open for adoption |
Under Development |
27: N/A, Androgen receptor, Antagonism |
337: N/A, Impairment of reproductive capacity |
|
|
| 13 |
Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities |
Anna Price |
Open for citation & comment |
Included in OECD Work Plan |
201: Binding of antagonist, NMDA receptors |
341: Impairment, Learning and memory |
WPHA/WNT Endorsed |
1.22 |
| 17 |
Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory |
Marie-Gabrielle Zurich |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1487: Binding, Thiol/seleno-proteins involved in protection against oxidative stress |
341: Impairment, Learning and memory |
EAGMST Under Review |
1.13 |
| 48 |
Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. |
Anna Price |
Open for citation & comment |
Included in OECD Work Plan |
875: Binding of agonist, Ionotropic glutamate receptors |
341: Impairment, Learning and memory |
WPHA/WNT Endorsed |
1.23 |
| 54 |
Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment |
Anna Price |
Open for citation & comment |
Included in OECD Work Plan |
424: Inhibition, Na+/I- symporter (NIS) |
341: Impairment, Learning and memory |
WPHA/WNT Endorsed |
1.28 |
| 38 |
Protein Alkylation leading to Liver Fibrosis |
Brigitte Landesmann |
Open for citation & comment |
Included in OECD Work Plan |
244: Alkylation, Protein |
344: N/A, Liver fibrosis |
WPHA/WNT Endorsed |
1.14 |
| 383 |
Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis |
Young Jun Kim |
Under development: Not open for comment. Do not cite |
|
1740: ACE2 inhibition |
344: N/A, Liver fibrosis |
|
|
| 144 |
Endocytic lysosomal uptake leading to liver fibrosis |
Marina Kuburic |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1539: Endocytotic lysosomal uptake |
344: N/A, Liver fibrosis |
EAGMST Under Review |
1.47 |
| 34 |
LXR activation leading to hepatic steatosis |
Marina Goumenou |
Not under active development |
Under Development |
167: Activation, LXR and 228: peroxisome proliferator activated receptor promoter demethylation |
345: N/A, Liver Steatosis |
|
|
| 327 |
Excessive reactive oxygen species production leading to mortality (1) |
You Song |
Under development: Not open for comment. Do not cite |
|
257: Increase, Reactive Oxygen Species production |
350: Increase, Mortality |
|
|
| 328 |
Excessive reactive oxygen species production leading to mortality (2) |
You Song |
Under development: Not open for comment. Do not cite |
|
257: Increase, Reactive Oxygen Species production |
350: Increase, Mortality |
|
|
| 329 |
Excessive reactive oxygen species production leading to mortality (3) |
You Song |
Under development: Not open for comment. Do not cite |
|
257: Increase, Reactive Oxygen Species production |
350: Increase, Mortality |
|
|
| 330 |
Excessive reactive oxygen species production leading to mortality (4) |
You Song |
Under development: Not open for comment. Do not cite |
|
257: Increase, Reactive Oxygen Species production |
350: Increase, Mortality |
|
|
| 331 |
Formation of DNA photoproducts leading to growth inhibition (1) |
You Song |
Under development: Not open for comment. Do not cite |
|
1765: Increase, Formation of DNA photoproducts |
350: Increase, Mortality |
|
|
| 342 |
S-adenosylmethionine depletion leading to population decline (1) |
You Song |
Under development: Not open for comment. Do not cite |
|
1522: Inhibition, Chitin synthase 1 |
350: Increase, Mortality |
|
|
| 343 |
S-adenosylmethionine depletion leading to population decline (2) |
You Song |
Under development: Not open for comment. Do not cite |
|
1525: Increase, Sulfonylurea receptor binding |
350: Increase, Mortality |
|
|
| 358 |
Chitinase inhibition leading to mortality |
Simon Schmid |
Under development: Not open for comment. Do not cite |
|
1806: Increase, Chitinase inhibition |
350: Increase, Mortality |
|
|
| 359 |
Chitobiase inhibition leading to mortality |
Simon Schmid |
Under development: Not open for comment. Do not cite |
|
1807: Increase, Chitobiase inhibition |
350: Increase, Mortality |
|
|
| 360 |
Chitin synthase 1 inhibition leading to mortality |
Simon Schmid |
Open for citation & comment |
Included in OECD Work Plan |
1522: Inhibition, Chitin synthase 1 |
350: Increase, Mortality |
EAGMST Under Review |
1.94 |
| 361 |
Sulfonylureareceptor binding leading to mortality |
Simon Schmid |
Under development: Not open for comment. Do not cite |
|
1525: Increase, Sulfonylurea receptor binding |
350: Increase, Mortality |
|
|
| 320 |
Binding of viral S-glycoprotein to ACE2 receptor leading to acute respiratory distress associated mortality |
Young Jun Kim |
Open for comment. Do not cite |
|
1739: ACE2 binding to viral S-protein |
351: Increased Mortality |
|
|
| 96 |
Axonal sodium channel modulation leading to acute mortality |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
598: modulation, sodium channel |
351: Increased Mortality |
|
1.29 |
| 104 |
Altered ion channel activity leading impaired heart function |
Kevin Dreher |
Under Development: Contributions and Comments Welcome |
Under Development |
697: impaired, ion channels |
351: Increased Mortality |
|
1.29 |
| 160 |
Ionotropic gamma-aminobutyric acid receptor activation mediated neurotransmission inhibition leading to mortality |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
Under Development |
762: Activation, ionotropic GABA Receptor chloride channel |
351: Increased Mortality |
|
|
| 161 |
Glutamate-gated chloride channel activation leading to neurotransmission inhibition associated mortality |
Knut Erik Tollefsen |
Under development: Not open for comment. Do not cite |
Under Development |
1018: Activation, Glutamate-gated chloride channels |
351: Increased Mortality |
|
|
| 186 |
unknown MIE leading to renal failure and mortality |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
1114: Unknown, MIE |
351: Increased Mortality |
|
1.29 |
| 16 |
Acetylcholinesterase inhibition leading to acute mortality |
Dan Villeneuve |
Under Development: Contributions and Comments Welcome |
Included in OECD Work Plan |
12: Acetylcholinesterase (AchE) Inhibition |
351: Increased Mortality and 360: Decrease, Population trajectory |
Under Development |
1.3 |
| 312 |
Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement |
Kristie Sullivan |
Under development: Not open for comment. Do not cite |
|
12: Acetylcholinesterase (AchE) Inhibition |
351: Increased Mortality and 360: Decrease, Population trajectory |
|
|
| 363 |
Thyroperoxidase inhibition leading to increased mortality via altered retinal layer structure |
Lucia Vergauwen |
Under development: Not open for comment. Do not cite |
|
279: Thyroperoxidase, Inhibition |
351: Increased Mortality and 360: Decrease, Population trajectory |
|
|
| 364 |
Thyroperoxidase inhibition leading to increased mortality via decreased eye size |
Lucia Vergauwen |
Under development: Not open for comment. Do not cite |
|
279: Thyroperoxidase, Inhibition |
351: Increased Mortality and 360: Decrease, Population trajectory |
|
|
| 365 |
Thyroperoxidase inhibition leading to increased mortality via altered photoreceptor patterning |
Lucia Vergauwen |
Under development: Not open for comment. Do not cite |
|
279: Thyroperoxidase, Inhibition |
351: Increased Mortality and 360: Decrease, Population trajectory |
|
|
| 399 |
Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) |
Vid Modic |
Under development: Not open for comment. Do not cite |
|
1884: Inhibition of Fyna |
351: Increased Mortality and 360: Decrease, Population trajectory |
|
|
| 155 |
Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation |
Dries Knapen |
Open for adoption |
Included in OECD Work Plan |
1002: Inhibition, Deiodinase 2 |
351: Increased Mortality and 360: Decrease, Population trajectory |
EAGMST Under Review |
1.35 |
| 156 |
Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation |
Dries Knapen |
Open for adoption |
Included in OECD Work Plan |
1002: Inhibition, Deiodinase 2 |
351: Increased Mortality and 360: Decrease, Population trajectory |
EAGMST Under Review |
1.35 |
| 157 |
Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation |
Dries Knapen |
Open for adoption |
Included in OECD Work Plan |
1009: Inhibition, Deiodinase 1 |
351: Increased Mortality and 360: Decrease, Population trajectory |
EAGMST Under Review |
1.35 |
| 158 |
Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation |
Dries Knapen |
Open for adoption |
Included in OECD Work Plan |
1009: Inhibition, Deiodinase 1 |
351: Increased Mortality and 360: Decrease, Population trajectory |
EAGMST Under Review |
1.35 |
| 159 |
Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation |
Dries Knapen |
Open for adoption |
Included in OECD Work Plan |
279: Thyroperoxidase, Inhibition |
351: Increased Mortality and 360: Decrease, Population trajectory |
EAGMST Under Review |
1.35 |
| 138 |
Organic anion transporter (OAT1) inhibition leading to renal failure and mortality |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
877: Inhibition, organic anion transporter 1 (OAT1) |
351: Increased Mortality and 361: Decline, Population |
|
1.29 |
| 177 |
Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
1103: Inhibition, Cyclooxygenase 1 activity |
351: Increased Mortality and 361: Decline, Population |
|
1.29 |
| 113 |
Glutamate-gated chloride channel activation leading to acute mortality |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
760: Activation, Glutamate-gated chloride channel |
351: Increased Mortality and 765: Decreased, population 1 |
|
1.29 |
| 281 |
Acetylcholinesterase Inhibition Leading to Neurodegeneration |
Karen Watanabe |
Under development: Not open for comment. Do not cite |
|
12: Acetylcholinesterase (AchE) Inhibition |
352: N/A, Neurodegeneration |
|
|
| 12 |
Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging |
Florianne Tschudi-Monnet |
Open for citation & comment |
Included in OECD Work Plan |
201: Binding of antagonist, NMDA receptors |
352: N/A, Neurodegeneration and 341: Impairment, Learning and memory |
WPHA/WNT Endorsed |
1.13 |
| 26 |
Calcium-mediated neuronal ROS production and energy imbalance |
Lyle Burgoon |
Open for adoption |
Under Development |
51: Inhibition, Ca++ ATPase |
356: Increased, Oxidative damage |
|
|
| 27 |
Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) |
Mathieu Vinken |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
41: Inhibition, Bile Salt Export Pump (ABCB11) |
357: Cholestasis, Pathology |
Under Development |
1.19 |
| 23 |
Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) |
Dan Villeneuve |
Open for citation & comment |
Included in OECD Work Plan |
25: Agonism, Androgen receptor |
360: Decrease, Population trajectory |
WPHA/WNT Endorsed |
1.12 |
| 25 |
Aromatase inhibition leading to reproductive dysfunction |
Dan Villeneuve |
Open for citation & comment |
Included in OECD Work Plan |
36: Inhibition, Aromatase |
360: Decrease, Population trajectory |
WPHA/WNT Endorsed |
1.12 |
| 30 |
Estrogen receptor antagonism leading to reproductive dysfunction |
Dan Villeneuve |
Open for citation & comment |
Included in OECD Work Plan |
112: Antagonism, Estrogen receptor |
360: Decrease, Population trajectory |
EAGMST Under Review |
1.12 |
| 289 |
Inhibition of 5α-reductase leading to impaired fecundity in female fish |
Young Jun Kim |
Open for citation & comment |
Included in OECD Work Plan |
1617: 5α-reductase, inhibition |
360: Decrease, Population trajectory |
Under Development |
1.81 |
| 292 |
Inhibition of tyrosinase leads to decreased population in fish |
Young Jun Kim |
Open for citation & comment |
Included in OECD Work Plan |
1627: Inhibition of tyrosinase |
360: Decrease, Population trajectory |
Under Development |
1.78 |
| 297 |
Inhibition of retinaldehyde dehydrogenase leads to population decline |
Young Jun Kim |
Under Development: Contributions and Comments Welcome |
Included in OECD Work Plan |
1637: Retinaldehyde dehydrogenase inhibition |
360: Decrease, Population trajectory |
Under Development |
1.77 |
| 334 |
Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration |
Alexander Cole |
Open for citation & comment |
|
122: Activation, Glucocorticoid Receptor |
360: Decrease, Population trajectory |
|
|
| 346 |
Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation |
Kelvin Santana Rodriguez |
Under Development: Contributions and Comments Welcome |
|
36: Inhibition, Aromatase |
360: Decrease, Population trajectory |
|
|
| 348 |
Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory |
Young Jun Kim |
Under development: Not open for comment. Do not cite |
|
1799: Inhibition of 11β-HSD |
360: Decrease, Population trajectory |
|
|
| 349 |
Inhibition of 11β-hydroxylase leading to decresed population trajectory |
Young Jun Kim |
Under development: Not open for comment. Do not cite |
|
1796: 11β-hydroxylase inhibition |
360: Decrease, Population trajectory |
|
|
| 376 |
Androgen receptor agonism leading to male-biased sex ratio |
Dan Villeneuve |
Open for citation & comment |
|
25: Agonism, Androgen receptor |
360: Decrease, Population trajectory |
|
|
| 29 |
Estrogen receptor agonism leading to reproductive dysfunction |
Tom Hutchinson |
Under Development: Contributions and Comments Welcome |
Under Development |
111: Agonism, Estrogen receptor |
360: Decrease, Population trajectory and 363: Altered, Reproductive behaviour and 339: Altered, Larval development and 364: Impaired development of, Reproductive organs |
|
1.29 |
| 131 |
Aryl hydrocarbon receptor activation leading to uroporphyria |
Amani Farhat |
Open for citation & comment |
Included in OECD Work Plan |
18: Activation, AhR |
369: Uroporphyria |
WPHA/WNT Endorsed |
1.7 |
| 46 |
AFB1: Mutagenic Mode-of-Action leading to Hepatocellular Carcinoma (HCC) |
Ted Simon |
Open for citation & comment |
Included in OECD Work Plan |
373: Formation, Pro-mutagenic DNA Adducts |
378: Tumorigenesis, Hepatocellular carcinoma |
EAGMST Under Review |
1.8 |
| 42 |
Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals |
Kevin Crofton |
Open for citation & comment |
Included in OECD Work Plan |
279: Thyroperoxidase, Inhibition |
402: Cognitive Function, Decreased |
WPHA/WNT Endorsed |
1.10 |
| 300 |
Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals |
Kevin Crofton |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1656: Antagonism, Thyroid Receptor |
402: Cognitive Function, Decreased |
Under Development |
1.84 |
| 134 |
Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals |
Mary Gilbert |
Under Development: Contributions and Comments Welcome |
Under Development |
424: Inhibition, Na+/I- symporter (NIS) |
402: Cognitive Function, Decreased |
|
1.29 |
| 405 |
Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function |
SAROJ AMAR |
Under development: Not open for comment. Do not cite |
|
12: Acetylcholinesterase (AchE) Inhibition |
402: Cognitive Function, Decreased |
|
|
| 152 |
Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity |
Kristie Sullivan |
Under Development: Contributions and Comments Welcome |
Included in OECD Work Plan |
957: Binding, Transthyretin in serum |
402: Cognitive Function, Decreased |
Under Development |
1.41 |
| 51 |
PPARα activation leading to impaired fertility in adult male rodents |
Elise Grignard |
Not under active development |
Included in OECD Work Plan |
227: Activation, PPARα |
406: impaired, Fertility |
Under Development |
1.21 |
| 64 |
Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility |
Susan Laws |
Under Development: Contributions and Comments Welcome |
Under Development |
494: Glucocorticoid Receptor Agonist, Activation |
406: impaired, Fertility |
|
1.29 |
| 18 |
PPARα activation in utero leading to impaired fertility in males |
Elise Grignard |
Open for citation & comment |
Included in OECD Work Plan |
227: Activation, PPARα |
406: impaired, Fertility and 348: Malformation, Male reproductive tract |
EAGMST Under Review |
1.21 |
| 7 |
Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female |
Elise Grignard |
Open for citation & comment |
Included in OECD Work Plan |
408: reduction in ovarian granulosa cells, Aromatase (Cyp19a1) |
406: impaired, Fertility and 405: irregularities, ovarian cycle |
EAGMST Under Review |
1.21 |
| 52 |
ER agonism leading to skewed sex ratios due to altered sexual differentiation in males |
Tom Hutchinson |
Under Development: Contributions and Comments Welcome |
Under Development |
111: Agonism, Estrogen receptor |
417: skewed, sex ratio |
|
1.29 |
| 218 |
Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity |
Florence Pagé-Larivière |
Not under active development |
Under Development |
1386: CYP7B activity, inhibition |
442: Decreased, Population trajectory |
|
|
| 219 |
Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior |
Florence Pagé-Larivière |
Not under active development |
Under Development |
1386: CYP7B activity, inhibition |
442: Decreased, Population trajectory |
|
|
| 57 |
AhR activation leading to hepatic steatosis |
Michelle Angrish |
Under Development: Contributions and Comments Welcome |
Under Development |
18: Activation, AhR |
455: Accumulation, Liver lipid |
|
1.29 |
| 36 |
Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis |
Michelle Angrish |
Under Development: Contributions and Comments Welcome |
Under Development |
231: Decreased, PPAR-alpha activation and 232: Decreased, PPAR-beta activation and 233: Decreased, PPAR-gamma activation |
459: Increased, Liver Steatosis |
|
1.29 |
| 58 |
NR1I3 (CAR) suppression leading to hepatic steatosis |
Michelle Angrish |
Under Development: Contributions and Comments Welcome |
Under Development |
456: Suppression, Constitutive androstane receptor, NR1l3 and 468: Inhibition, PPAR alpha and 167: Activation, LXR and 228: peroxisome proliferator activated receptor promoter demethylation |
459: Increased, Liver Steatosis |
|
1.29 |
| 60 |
NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis |
Michelle Angrish |
Under Development: Contributions and Comments Welcome |
Under Development |
245: Activation, PXR/SXR |
459: Increased, Liver Steatosis |
|
1.29 |
| 61 |
NFE2L2/FXR activation leading to hepatic steatosis |
Michelle Angrish |
Under Development: Contributions and Comments Welcome |
Under Development |
478: Activation, NRF2 and 479: Activation, NR1H4 |
459: Increased, Liver Steatosis |
|
1.29 |
| 62 |
AKT2 activation leading to hepatic steatosis |
Michelle Angrish |
Under Development: Contributions and Comments Welcome |
Under Development |
486: systemic inflammation leading to hepatic steatosis |
459: Increased, Liver Steatosis |
|
1.29 |
| 318 |
Glucocorticoid Receptor activation leading to hepatic steatosis |
Chander K. Negi |
Under Development: Contributions and Comments Welcome |
|
122: Activation, Glucocorticoid Receptor |
459: Increased, Liver Steatosis |
|
|
| 66 |
Modulation of Adult Leydig Cell Function Subsequent Glucocorticoid Activation in the Fetal Testis |
Gary Klinefelter |
Under Development: Contributions and Comments Welcome |
Under Development |
653: Decreased testosterone by the fetal Leydig cells, Increased corticosterone and 654: Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists |
505: Decreased sperm quantity / quality in the adult, Decreased fertility |
|
1.29 |
| 67 |
Modulation of Adult Leydig Cell Function Subsequent to Estradiaol Activation in the Fetal Testis |
Gary Klinefelter |
Under Development: Contributions and Comments Welcome |
Under Development |
658: Decreased testosterone by the fetal Leydig cells, Increased estradiol and 659: Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists |
505: Decreased sperm quantity / quality in the adult, Decreased fertility |
|
1.29 |
| 68 |
Modulation of Adult Leydig Cell Function Subsequent to Alterations in the Fetal Testis Protome |
Gary Klinefelter |
Under Development: Contributions and Comments Welcome |
Under Development |
661: Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome |
505: Decreased sperm quantity / quality in the adult, Decreased fertility |
|
1.29 |
| 70 |
Modulation of Adult Leydig Cell Function Subsequent to Proteomic Alterations in the Adult Leydig Cell |
Gary Klinefelter |
Under Development: Contributions and Comments Welcome |
Under Development |
640: Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell |
520: Decreased sperm quantity or quality in the adult, Decreased fertility |
|
1.29 |
| 71 |
Modulation of Adult Leydig Cell Function Subsequent to Glucocorticoid Activation |
Gary Klinefelter |
Under Development: Contributions and Comments Welcome |
Under Development |
650: Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid |
520: Decreased sperm quantity or quality in the adult, Decreased fertility |
|
1.29 |
| 73 |
Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity |
Tammy Stoker |
Under Development: Contributions and Comments Welcome |
Under Development |
526: Inhibition, Inhibition of Dopamine-beta-hydroxylase |
527: Decreased, Decreased fecundity |
|
1.29 |
| 126 |
Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation |
Tammy Stoker |
Under Development: Contributions and Comments Welcome |
Under Development |
849: Inhibition, Antgonism of NE receptor |
527: Decreased, Decreased fecundity |
|
1.29 |
| 74 |
Modulation of Adult Leydig Cell Function Subsequent to Hypermethylation in the Fetal Testis |
Gary Klinefelter |
Under Development: Contributions and Comments Welcome |
Under Development |
662: Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis |
543: Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis |
|
1.29 |
| 77 |
Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
559: Activation, Nicotinic acetylcholine receptor |
563: Death/Failure, Colony |
|
1.29 |
| 79 |
Nicotinic acetylcholine receptor activation contributes to impaired hive thermoregulation and leads to colony loss/failure |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
559: Activation, Nicotinic acetylcholine receptor |
563: Death/Failure, Colony |
|
1.29 |
| 87 |
Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
559: Activation, Nicotinic acetylcholine receptor |
563: Death/Failure, Colony |
|
1.29 |
| 88 |
Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
559: Activation, Nicotinic acetylcholine receptor |
563: Death/Failure, Colony |
|
1.29 |
| 89 |
Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
559: Activation, Nicotinic acetylcholine receptor |
563: Death/Failure, Colony |
|
1.29 |
| 178 |
Nicotinic acetylcholine receptor activation contributes to mitochondrial dysfunction and leads to colony loss/failure |
Carlie LaLone |
Under Development: Contributions and Comments Welcome |
Under Development |
559: Activation, Nicotinic acetylcholine receptor |
563: Death/Failure, Colony |
|
1.29 |
| 179 |
Varroa mite infestation increases virus levels leading to colony loss/failure |
Carlie LaLone |
Under Development: Contributions and Comments Welcome |
Under Development |
|
563: Death/Failure, Colony |
|
1.29 |
| 180 |
Varroa mite infestation contributes to abnormal foraging leading to colony loss/failure |
Carlie LaLone |
Under Development: Contributions and Comments Welcome |
Under Development |
|
563: Death/Failure, Colony |
|
1.29 |
| 181 |
Weather event contributes to colony loss/failure |
Carlie LaLone |
Under Development: Contributions and Comments Welcome |
Under Development |
|
563: Death/Failure, Colony |
|
1.29 |
| 182 |
Weather event contributes abnormal foraging leading to colony loss/failure |
Carlie LaLone |
Under Development: Contributions and Comments Welcome |
Under Development |
|
563: Death/Failure, Colony |
|
1.29 |
| 183 |
Nosema infection increases energetic demands leading to colony loss/failure |
Carlie LaLone |
Under Development: Contributions and Comments Welcome |
Under Development |
|
563: Death/Failure, Colony |
|
1.29 |
| 184 |
Nosema infection causes abnormal role change that leads to colony loss/failure |
Carlie LaLone |
Under Development: Contributions and Comments Welcome |
Under Development |
|
563: Death/Failure, Colony |
|
1.29 |
| 185 |
Queen egg-laying decrease leads to colony loss/failure |
Carlie LaLone |
Under Development: Contributions and Comments Welcome |
Under Development |
|
563: Death/Failure, Colony |
|
1.29 |
| 78 |
Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
559: Activation, Nicotinic acetylcholine receptor |
566: impaired, Larval development and 563: Death/Failure, Colony |
|
1.29 |
| 82 |
Abnormal role change in worker caste contributes to reduced brood care and leads to colony loss/failure |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
|
566: impaired, Larval development and 563: Death/Failure, Colony |
|
1.29 |
| 86 |
Decrease Glucose oxidase activity contributes to reduction of antiseptic in food and leads to colony loss/failure |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
|
566: impaired, Larval development and 563: Death/Failure, Colony |
|
1.29 |
| 90 |
Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
559: Activation, Nicotinic acetylcholine receptor |
566: impaired, Larval development and 563: Death/Failure, Colony |
|
1.29 |
| 81 |
Increased metabolic stress contributes to abnormal foraging and leads to colony loss/failure |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
|
572: Decrease, Number of worker bees and 563: Death/Failure, Colony |
|
1.29 |
| 85 |
Suppression of immune system contributes to abnormal foraging and leads to colony loss/failure |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
|
572: Decrease, Number of worker bees and 563: Death/Failure, Colony |
|
1.29 |
| 80 |
Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
559: Activation, Nicotinic acetylcholine receptor |
572: Decrease, Number of worker bees and 568: impaired, Hive thermoregulation and 563: Death/Failure, Colony |
|
1.29 |
| 84 |
Suppression of immune system contributes to impaired development and leads to colony loss/failure |
Carlie LaLone |
Open for comment. Do not cite |
Under Development |
|
572: Decrease, Number of worker bees and 568: impaired, Hive thermoregulation and 563: Death/Failure, Colony |
|
1.29 |
| 91 |
Sodium channel inhibition leading to reduced survival |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
584: Inhibition, sodium channel |
587: Reduced, feeding 1 and 588: Increased, predation and 592: Reduced, survival |
|
1.29 |
| 93 |
sodium channel inhibition leading to increased predation |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
584: Inhibition, sodium channel |
588: Increased, predation |
|
1.29 |
| 98 |
5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to decreased shelter seeking and increased predation |
Ksenia Groh |
Under Development: Contributions and Comments Welcome |
|
619: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
588: Increased, predation |
|
1.29 |
| 94 |
Sodium channel inhibition leading to congenital malformations |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
584: Inhibition, sodium channel |
591: Increased, amputations |
|
1.29 |
| 95 |
Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
593: Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel |
592: Reduced, survival |
|
1.29 |
| 10 |
Binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain |
Ping Gong |
Open for citation & comment |
Included in OECD Work Plan |
667: Binding at picrotoxin site, iGABAR chloride channel |
613: Occurrence, Epileptic seizure |
WPHA/WNT Endorsed |
1.15 |
| 97 |
5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
619: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
623: Increase, predation and 361: Decline, Population |
|
1.29 |
| 99 |
Histamine (H2) receptor antagonism leading to reduced survival |
Kellie Fay |
Under Development: Contributions and Comments Welcome |
Under Development |
638: Antagonism, Histamine Receptor (H2) |
636: Decreased, survival and 588: Increased, predation |
|
1.29 |
| 69 |
Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell |
Gary Klinefelter |
Under Development: Contributions and Comments Welcome |
Under Development |
642: Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol and 643: Decreased Cholesterol, Decreased Uptake of Lipoproteins and 644: Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membrane |
646: Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis |
|
1.29 |
| 63 |
Cyclooxygenase inhibition leading to reproductive dysfunction |
Dalma Martinovic-Weigelt |
Under Development: Contributions and Comments Welcome |
Under Development |
79: Inhibition, Cyclooxygenase activity |
675: Reduced, Reproductive Success and 360: Decrease, Population trajectory |
|
1.29 |
| 100 |
Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior |
Dalma Martinovic-Weigelt |
Under Development: Contributions and Comments Welcome |
Under Development |
79: Inhibition, Cyclooxygenase activity |
675: Reduced, Reproductive Success and 360: Decrease, Population trajectory |
|
1.29 |
| 101 |
Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release |
Dalma Martinovic-Weigelt |
Under Development: Contributions and Comments Welcome |
Under Development |
79: Inhibition, Cyclooxygenase activity |
675: Reduced, Reproductive Success and 360: Decrease, Population trajectory |
|
1.29 |
| 102 |
Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition |
Dalma Martinovic-Weigelt |
Under Development: Contributions and Comments Welcome |
Under Development |
79: Inhibition, Cyclooxygenase activity |
675: Reduced, Reproductive Success and 360: Decrease, Population trajectory |
|
1.29 |
| 103 |
Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint |
Dalma Martinovic-Weigelt |
Under Development: Contributions and Comments Welcome |
Under Development |
79: Inhibition, Cyclooxygenase activity |
675: Reduced, Reproductive Success and 360: Decrease, Population trajectory |
|
1.29 |
| 309 |
Luteinizing hormone receptor antagonism leading to reproductive dysfunction |
Young Jun Kim |
Under Development: Contributions and Comments Welcome |
|
1691: Antagonism,LH receptor |
679: Decline, Population trajectory |
|
|
| 105 |
Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
714: Increased, Binding of chemicals to 2u (serum) |
713: Increase, Adenomas/carcinomas (renal tubular) |
|
1.29 |
| 116 |
Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
783: Increase, Cytotoxicity (tubular epithelial cells) |
713: Increase, Adenomas/carcinomas (renal tubular) |
|
1.29 |
| 37 |
PPARα activation leading to hepatocellular adenomas and carcinomas in rodents |
Chris Corton |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
227: Activation, PPARα |
719: Increase, hepatocellular adenomas and carcinomas |
Under Development |
1.17 |
| 107 |
Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat |
Kristin Lichti-Kaiser |
Open for citation & comment |
Included in OECD Work Plan |
715: Activation, Constitutive androstane receptor |
719: Increase, hepatocellular adenomas and carcinomas |
EAGMST Under Review |
1.17 |
| 108 |
Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
724: Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme |
719: Increase, hepatocellular adenomas and carcinomas |
|
1.29 |
| 117 |
Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) |
Charles Wood |
Open for adoption |
Included in OECD Work Plan |
785: Activation, Androgen receptor |
719: Increase, hepatocellular adenomas and carcinomas |
Under Development |
1.26 |
| 118 |
Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
786: Increase, Cytotoxicity (hepatocytes) |
719: Increase, hepatocellular adenomas and carcinomas |
|
1.29 |
| 106 |
Chemical binding to tubulin in oocytes leading to aneuploid offspring |
Francesco Marchetti |
Open for citation & comment |
Included in OECD Work Plan |
718: Binding, Tubulin |
728: Increase, Aneuploid offspring |
EAGMST Under Review |
1.11 |
| 109 |
Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
770: Increase, Cytotoxicity (club cells) |
736: Increase, Adenomas/carcinomas (bronchioloalveolar) |
|
1.29 |
| 110 |
Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
737: Decreased, Uptake of inorganic iodide |
741: Increase, Adenomas/carcinomas (follicular cell) |
|
1.29 |
| 119 |
Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
279: Thyroperoxidase, Inhibition |
741: Increase, Adenomas/carcinomas (follicular cell) |
|
1.29 |
| 111 |
Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
742: Decreased, Androgen receptor activity |
745: Increase, Leydig cell tumors |
|
1.29 |
| 120 |
Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
790: Inhibition, 5α-reductase activity |
745: Increase, Leydig cell tumors |
|
1.29 |
| 33 |
Kidney toxicity induced by activation of 5HT2C |
Kevin Crofton |
Open for adoption |
Under Development |
9: Activation, 5HT2c |
759: Increased, Kidney Failure |
|
|
| 112 |
Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
746: Increase, Dopaminergic activity |
773: Increase, Endometrial adenocarcinomas |
|
1.29 |
| 114 |
HPPD inhibition leading to corneal papillomas and carcinomas (in rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
766: Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme |
779: Increase, Papillomas/carcinomas (squamous cells) |
|
1.29 |
| 115 |
Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
780: Increase, Cytotoxicity (epithelial cells) |
779: Increase, Papillomas/carcinomas (squamous cells) |
|
1.29 |
| 271 |
Inhibition of thyroid peroxidase leading to impaired fertility in fish |
June-Woo Park |
Open for comment. Do not cite |
Included in OECD Work Plan |
279: Thyroperoxidase, Inhibition |
78: Reduction, Cumulative fecundity and spawning |
Under Development |
1.59 |
| 310 |
Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR |
Jon Doering |
Under development: Not open for comment. Do not cite |
|
18: Activation, AhR |
78: Reduction, Cumulative fecundity and spawning and 360: Decrease, Population trajectory |
|
|
| 122 |
Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation |
Dalma Martinovic-Weigelt |
Under Development: Contributions and Comments Welcome |
Under Development |
798: Inhibition, Prolyl hydroxylases |
78: Reduction, Cumulative fecundity and spawning and 360: Decrease, Population trajectory |
|
1.29 |
| 123 |
Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription |
Dalma Martinovic-Weigelt |
Under Development: Contributions and Comments Welcome |
Under Development |
801: modulation, Unknown |
78: Reduction, Cumulative fecundity and spawning and 360: Decrease, Population trajectory |
|
1.29 |
| 121 |
Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) |
Charles Wood |
Under Development: Contributions and Comments Welcome |
Under Development |
793: Increase, Urinary bladder calculi |
797: Increase, Adenomas/carcinomas (urothelial) |
|
1.29 |
| 256 |
Inhibition of mitochondrial DNA polymerase gamma leading to kidney toxicity |
Angela Mally |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1481: Inhibition of mitochondrial DNA polymerase gamma (Pol gamma) |
814: Occurrence, Kidney toxicity |
Under Development |
1.43 |
| 257 |
Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity |
Angela Mally |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
1486: Binding of substrate, endocytic receptor |
814: Occurrence, Kidney toxicity |
Under Development |
1.43 |
| 258 |
Renal protein alkylation leading to kidney toxicity |
Angela Mally |
Not under active development |
Included in OECD Work Plan |
244: Alkylation, Protein |
814: Occurrence, Kidney toxicity |
Under Development |
1.43 |
| 128 |
Kidney dysfunction by decreased thyroid hormone |
Jung-Hwa Oh |
Under development: Not open for comment. Do not cite |
Included in OECD Work Plan |
277: Thyroid hormone synthesis, Decreased |
814: Occurrence, Kidney toxicity |
Under Development |
1.40 |
| 40 |
Covalent Protein binding leading to Skin Sensitisation |
Sharon Munn |
Open for citation & comment |
Included in OECD Work Plan |
396: Covalent Binding, Protein |
827: sensitisation, skin |
WPHA/WNT Endorsed |
1.1 |
| 130 |
Phospholipase A inhibitors lead to hepatotoxicity |
Jung-Hwa Oh |
Under Development: Contributions and Comments Welcome |
Included in OECD Work Plan |
828: Inhibition, Phospholipase A |
840: Formation, Liver fibrosis |
Under Development |
1.39 |
| 41 |
Sustained AhR Activation leading to Rodent Liver Tumours |
Rick Becker |
Open for citation & comment |
Included in OECD Work Plan |
165: Activation, Long term AHR receptor driven direct and indirect gene expression changes |
856: Formation, Hepatocellular and Bile duct tumors |
EAGMST Under Review |
1.7 |
| 6 |
Antagonist binding to PPARα leading to body-weight loss |
Kurt A. Gust |
Open for citation & comment |
Included in OECD Work Plan |
998: Binding of antagonist, PPAR alpha |
864: Decreased, Body Weight |
WPHA/WNT Endorsed |
2.3 |
| 368 |
Cytochrome oxidase inhibition leading to olfactory nasal lesions |
Katy Goyak |
Under development: Not open for comment. Do not cite |
|
1840: Inhibition, cytochrome oxidase |
872: Increase, Site of Contact Nasal Tumors |
|
|
| 136 |
Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors |
Justin Teeguarden |
Open for citation & comment |
Included in OECD Work Plan |
867: Decrease, Intracellular pH |
872: Increase, Site of Contact Nasal Tumors |
EAGMST Under Review |
2.7 |
| 139 |
Alkylation of DNA leading to cancer 1 |
Carole Yauk |
Open for adoption |
Under Development |
97: Alkylation, DNA |
885: Increase, Cancer |
|
|
| 3 |
Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits |
Andrea Terron |
Open for citation & comment |
Included in OECD Work Plan |
888: Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) |
896: Parkinsonian motor deficits |
WPHA/WNT Endorsed |
1.33 |
| 150 |
Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF |
Amani Farhat |
Open for citation & comment |
Included in OECD Work Plan |
18: Activation, AhR |
947: Increase, Early Life Stage Mortality |
WPHA/WNT Endorsed |
1.7 |
| 149 |
Peptide Oxidation Leading to Hypertension |
Frazer Lowe |
Not under active development |
Included in OECD Work Plan |
209: Peptide Oxidation |
952: Hypertension |
Under Development |
1.50 |
| 345 |
Androgen receptor (AR) antagonism leading to decreased fertility in females |
Terje Svingen |
Under development: Not open for comment. Do not cite |
|
26: Antagonism, Androgen receptor |
972: Decreased fertility, Reduced number of oocytes ovulated |
|
|
| 398 |
Inhibition of ALDH1A2 (RALDH2) causing reduced all-trans retinoic acid levels leading to decreased fertility, females |
Terje Svingen |
Under development: Not open for comment. Do not cite |
|
1880: Inhibition of ALDH1A2 (RALDH2) |
972: Decreased fertility, Reduced number of oocytes ovulated |
|
|
| 153 |
Aromatase Inhibition leading to Ovulation Inhibition and Decreased Fertility in Female Rats |
Tammy Stoker |
Under Development: Contributions and Comments Welcome |
Under Development |
964: Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol |
972: Decreased fertility, Reduced number of oocytes ovulated |
|
1.29 |
| 154 |
Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response |
Takumi Ohishi |
Open for comment. Do not cite |
Included in OECD Work Plan |
980: Inhibition, Calcineurin Activity |
984: Impairment, T-cell dependent antibody response |
EAGMST Under Review |
1.38 |
| 277 |
Impaired IL-1R1 signaling leading to increased susceptibility to infection |
Yutaka Kimura |
Open for citation & comment |
Included in OECD Work Plan |
1700: Impaired IL-1R1 signaling |
986: Increase, Increased susceptibility to infection |
EAGMST Under Review |
1.48 |